Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

VRB-101

Stage Phase 2Stale

Sponsor Verdiva Bio Dev Limited

Route oral

Sources

registry, as of 2026-08-17Stale

https://clinicaltrials.gov/study/NCT07281937

A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status COMPLETED. Phases PHASE2. Lead sponsor Verdiva Bio Dev Limited. Enrollment 206. Conditions Obesity; Overweight. The aim of this study is to evaluate the efficacy of VRB-101 for body weight reduction compared to placebo in participants who have obesity or overweight with weight-related comorbidities.

ClinicalTrials.gov NCT07281937 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07553299

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities. Overall status TERMINATED. Phases PHASE2. Lead sponsor Verdiva Bio Dev Limited. Enrollment 8. Conditions Obesity; Overweight; Weight Maintenance. The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.

ClinicalTrials.gov NCT07553299 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07628127

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight. Overall status RECRUITING. Phases PHASE1. Lead sponsor Verdiva Bio Dev Limited. Enrollment 332. Conditions Obesity; Overweight. The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.

ClinicalTrials.gov NCT07628127 protocol and results modules

Studies

EVOLVE-2

Registry NCT07281937

Phase Phase 2

Status Completed

Enrollment 206

Start 2025-11-25

Primary completion 2026-07-23

Study completion 2026-07-23

Catalyst Primary completion. 2026-07-23. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Schedule A: VRB-101 (Active Arm 1)

Regimen weekly

Comparator placebo

Population Obesity; Overweight

Schedule A: VRB-101 (Active Arm 2)

Regimen weekly

Comparator placebo

Population Obesity; Overweight

Schedule A: VRB-101 (Active Arm 3)

Regimen weekly

Comparator placebo

Population Obesity; Overweight

Schedule B: VRB-101 (Active Arm 4)

Regimen weekly

Comparator placebo

Population Obesity; Overweight

Schedule B: VRB-101 (Active Arm 5)

Regimen weekly

Comparator placebo

Population Obesity; Overweight

Pooled Placebo

Regimen weekly

Population Obesity; Overweight

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Registry NCT07553299

Phase Phase 2

Status Terminated

Enrollment 8

Start 2026-06-12

Primary completion 2026-09-11

Study completion 2026-09-11

Catalyst Primary completion. 2026-09-11. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

VRB-101 (Active Arm 1)

Regimen weekly

Comparator placebo

Population Obesity; Overweight; Weight Maintenance

VRB-101 (Active Arm 2)

Regimen weekly

Comparator placebo

Population Obesity; Overweight; Weight Maintenance

VRB-101 (Active Arm 3)

Regimen weekly

Comparator placebo

Population Obesity; Overweight; Weight Maintenance

Placebo

Regimen weekly

Population Obesity; Overweight; Weight Maintenance

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

Registry NCT07628127

Phase Phase 1

Status Recruiting

Enrollment 332

Start 2026-07-06

Arm 1, SAD

Population Obesity; Overweight

Arm 2, MAD

Population Obesity; Overweight

Arm 3, MAD

Population Obesity; Overweight